First migraine prevention drug hits EU market
Swiss pharma giant Novartis announced that its monoclonal antibody for migraine prevention Aimovig (erenumab) has received market approval in the EU. It is the first treatment of its kind to […]
Author Archive for: UM
About Uta Mommert
This author has not written his bio yet.
But we are proud to say that Uta Mommert contributed 42 entries already.
Entries by Uta Mommert
Nanobiotix signs 40m deal with EIB
/in News/by Uta MommertA financing agreement with the European Investment Bank will allow the French cancer specialist Nanobiotix to borrow up to 40m through loan money the company needs to boost its […]
CRISPR & Co are GMOs, says EU court
/in News/by Uta MommertThe EU Court of Justice has ruled that plants created using novel genome editing methods will be classed as genetically modified organisms and therefore have to follow the strict EU […]
Nabriva nabs market-ready antibiotic
/in News/by Uta MommertIrish Nabriva Therapeutics plc has acquired San Diego-based antibiotics developer Zavante Therapeutics for 8.2 million shares plus US$97.5m in milestone payments.
TxCell snapped up by Sangamo
/in News/by Uta MommertUS gene editing expert Sangamo Therapeutics is set to acquire French biotech TxCell in an all-cash buyout of 72m on a debt- and cash-free basis.
Sobi in 387m orphan drug deal with Novimmune
/in News/by Uta MommertSwedish Orphan Biovitrum AB (Sobi) has signed a 387 deal with Swiss drug developer Novimmune for a late stage antibody targeting a rare haematology disorder.
Novartis pays 945m for eczema programme
/in News/by Uta MommertEuropean biotechs Morphosys and Galapagos have handed over their joint atopical dermatitis programme MOR106 to Novartis for up to 945m. The Swiss pharma giant aims to strengthen its commitment to […]
IMI to spur on antibiotics research amidst big pharma pullback
/in News/by Uta MommertThe Innovative Medicines Initiative has launched a new Antimicrobial Resistance Accelerator Programme after Novartis announced its retreat from antibiotics research only days ago.
Roche granted breakthrough status for liver cancer combo
/in News/by Uta MommertRoche announced today that the US-American Food and Drug Administration FDA has granted Breakthrough Therapy designation for the Swiss pharma giants mAb combination therapy for liver cancer.
Epigenetic biomarkers predict immunotherapy success
/in News/by Uta MommertUK biotech Oxford BioDynamics has presented data showing that the companys blood test can predict patient response to treatment with immune checkpoint inhibitors anti-PD-1 and anti-PD-L1.